Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Genes2me LLP "Transforming Preventive health and Women & Child health in 1.2B people"

Genes2me is a genomics driven advanced diagnostic company creating a benchmark in the field of personalised healthcare and genetic screening with a focused segments into Preventive health, Oncology, Mother & Child health and Pharmacogenomics.

The translational approach to enhance global health even in resource limited areas by being cost effective, technologically driven, with a 360 degree overview of complete diagnostic proposition under one test.

Keeping innovation at the forefront and an access to clinically relevant samples having history, has backed Genes2me with insights into complex genetic diseases to ideate, create and evaluate to develop the best in class preventive, diagnostics and genetic based products and transform personalised Health.

Having state of the art facility established with all leading genomics and clinical diagnostics technologies installed and team of more than 75 experts in assay development, validation, scientific team, business development.

  • Date:Monday, February 11
  • Time:3:00 PM - 3:15 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23467
  • Goal for Presentation:Introduction to Bio-industry / Investors & Seeking funding
  • Company Website:www.genes2me.com
  • Company HQ City:Gurugram (New Delhi Region)
  • Company HQ Country:India
  • Total Amount Raised to Date, in All Rounds:NIL
  • Previous and Current Investors:Self Funded
  • CEO/Top Company Official:Neeraj Gupta
  • Year Founded:Dec 2016
  • Main Therapeutic Focus:Diagnostics
  • Lead Product in Development:Preventive healthcare segment
  • Development Phase of Primary Product:Multiple Products in Market
  • Additional Information/Comments:We are bringing a new paradigm change in the way the preventive health market is done, we are coupling the routine clinical diagnostics and genetic pre-disposition, Pgx information on personalised medicine into one "Healthyme" package at affordable price. We have developed multiple assays in this segment for personalised health and wellness, such as lifestyle traits, health conditions, women health, Nutrition, etc. We have extensive solutions for all pre/post-natal diagnostic and early screening for multiple genetic disorders such as NIPT, Beta-thalassemmia & sickle cell, SMA, Fragile X, Thrombophilia, DMD, CMA, Clinical exome. In oncology segment we have developed very comprehensive BRACA gene testing, liquid biopsy based lung & colon cancer based assays. Many assays are in development. Further plans to introduce a large Pharmacogenomics PGX screening program on Indian diverse population for various drug effects.
Speakers
Neeraj Gupta
Genes2me LLP
Back